Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease: Clinical Evidence, Pharmacology, and Drug-Drug Interactions for Personalized Management of Hyperkalemia. [PDF]
Int J Mol SciHirai T, Katayama K.
europepmc +1 more source
Effects of spironolactone on cytotoxic damage in osteoblasts. [PDF]
Exp Ther MedPark SY +5 more
europepmc +1 more source
Metoprolol-spironolactone combination for coronary heart disease with concurrent heart failure: impact on cardiac function. [PDF]
Am J Transl ResZhao S, Zhang J, Zhao Y.
europepmc +1 more source
Mineralocorticoid receptor antagonists: Efficacy and safety in chronic kidney disease. [PDF]
Diabetes Obes MetabMottl AK, Khunti K, Mathieu C.
europepmc +1 more source
Drug-Resistant Sinus Tachycardia as a Dose-Dependent Side Effect of Spironolactone: A Case Report and Review of the Literature. [PDF]
Clin Case RepAbdi Z +3 more
europepmc +1 more source
Comparative Effects of Mineralocorticoid Receptor Antagonism on Organ Dysfunction in COVID-19-Associated ARDS. [PDF]
BiomedicinesDumanlı GY +5 more
europepmc +1 more source
Sustained remission of post-Fontan protein-losing enteropathy achieved by combination therapy with high-dose spironolactone and the somatostatin analogue octreotide: a case report. [PDF]
BMC PediatrSuzuki E +10 more
europepmc +1 more source
Concomitant Enalapril and Spironolactone-Induced Hyperkalemia in a Pediatric Patient. [PDF]
J Pediatr Pharmacol TherRogado SM +4 more
europepmc +1 more source
Effect of anti-fibrotic therapy on regression of myocardial fibrosis after TAVI: design and rationale of the Reduce-MFA DZHK25 trial. [PDF]
ESC Heart FailPuls M +11 more
europepmc +1 more source
Add-On Spironolactone for Persistent Proteinuria After Sodium-Glucose Cotransporter 2 Inhibitor Therapy in Patients With Diabetic Kidney Disease: A Retrospective Observational Study. [PDF]
CureusSugiyama S +8 more
europepmc +1 more source